PressJanuary 17, 2025 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
PressJanuary 17, 2025 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
PressJanuary 17, 2025 Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
PressJanuary 17, 2025 Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
PressJanuary 13, 2025 atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
PressJanuary 6, 2025 Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
PressJanuary 6, 2025 Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
PressJanuary 6, 2025 SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
PressJanuary 6, 2025 Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
PressJanuary 4, 2025 Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
PressJanuary 2, 2025 Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
PressJanuary 2, 2025 Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
PressDecember 26, 2024 Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
PressDecember 23, 2024 Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
PressDecember 23, 2024 PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
PressDecember 20, 2024 Jaguar Health Announces Import of Coca Leaf from Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
PressDecember 19, 2024 Psyence Biomedical : Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial Form 6K
